Standout Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or mic... 2014 2026 2018 2022 1.9k
  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (2017)
    Michael J. Overman, Ray McDermott et al. The Lancet Oncology
  2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer (2018)
    Michael J. Overman, Sara Lonardi et al. Journal of Clinical Oncology
  3. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study (2015)
    Chiara Cremolini, Fotios Loupakis et al. The Lancet Oncology
  4. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer (2014)
    Fotios Loupakis, Chiara Cremolini et al. New England Journal of Medicine
  5. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study (2015)
    Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology
  6. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial (2011)
    C. Aschele, L. Cionini et al. Journal of Clinical Oncology
  7. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer (2021)
    Yelena Y. Janjigian, Akihito Kawazoe et al. Nature
  8. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023)
    Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet
  9. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 (2022)
    Thierry André, Sara Lonardi et al. Annals of Oncology
  10. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study (2023)
    Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology

Immediate Impact

3 by Nobel laureates 9 from Science/Nature 67 standout
Sub-graph 1 of 22

Citing Papers

Pancreatic cancer
2025 Standout
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization
2025 Standout

Works of Sara Lonardi being referenced

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
2021
and 1 more

Author Peers

Author Last Decade Papers Cites
Sara Lonardi 10511 3838 3476 464 13.3k
Takayuki Yoshino 11568 5388 4126 697 15.3k
Niall C. Tebbutt 9052 4293 2549 250 12.5k
Johanna C. Bendell 9252 4273 1978 530 14.4k
Jean‐Baptiste Bachet 11132 4076 1806 210 13.2k
Yves Humblet 12675 5501 2767 174 15.6k
Jeeyun Lee 7417 6559 2451 502 14.0k
Ho Yeong Lim 6235 5478 2364 365 14.2k
Christophe Louvet 14592 5964 2378 278 17.4k
Ian Chau 12763 6982 2528 463 18.2k
Gunnar Folprecht 8392 3539 2408 197 10.4k

All Works

Loading papers...

Rankless by CCL
2026